Lingbei

Lingbei Biopharma is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative peptide-based therapeutics for metabolic diseases. The company focuses on multi-agonist peptides targeting the Glucagon-like peptide 1 receptor (GLP-1R), Gastric inhibitory polypeptide receptor (GIPR), and Glucagon receptor (GCGR) to treat conditions such as obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Their lead program, LB-101, is a long-acting triple agonist designed to provide superior weight loss and glycemic control compared to existing mono- or dual-agonists. Lingbei leverages a proprietary peptide optimization platform to enhance the stability, potency, and pharmacokinetic profiles of its drug candidates. The company is supported by leading venture capital firms, including Qiming Venture Partners and IDG Capital. Lingbei aims to advance its pipeline through global clinical development to address the growing global burden of metabolic disorders.